Safety Study of Recombinant Vaccinia Virus to Treat Refractory Solid Tumors in Pediatric Patients

NCT01169584 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

6

Enrollment

INDUSTRY

Sponsor class

Conditions

Neuroblastoma
Rhabdomyosarcoma
Lymphoma
Wilm's Tumor
Ewing's Sarcoma

Interventions

DRUG: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)

Sponsor

Jennerex Biotherapeutics

Collaborators

[object Object]